Please login to the form below

Not currently logged in
Email:
Password:

chronic lymphocytic leukaemia

This page shows the latest chronic lymphocytic leukaemia news and features for those working in and with pharma, biotech and healthcare.

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

The drug has been approved for chronic lymphocytic leukaemia (CLL) since 2016 and picked up a second indication in acute myeloid leukaemia (AML) last year, but analyst Steve Scala at Cowen

Latest news

More from news
Approximately 12 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area.

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    chronic lymphocytic leukaemia and relapsed B-cell ALL. ... The course of MDS is highly variable, and around one-third of patients develop acute myeloid leukaemia (AML).

  • Therapy Watch expands oncology and IBD portfolios

    This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... Therapy Watch CML is part of a wider oncology

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics